GDRXNasdaqServices-Computer Processing & Data PreparationFiscal year ends December 31
GoodRx Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$3.37+0.01 (+0.30%)
Close on Oct 19, 2026
- Market cap
- $1.17B
- P/E (TTM)
- 84.3
- Dividend yield
- –
GoodRx Holdings, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prescription transactions revenue | $106.39M | $113.69M | $124.72M | $127.29M | $143.06M | $148.92M | $144.99M | $140.42M | $146.75M | $145.40M | $143.86M | $135.43M | 53.1% | -25.6% |
| Pharma Direct revenue | $61.63M | $52.23M | – | $43.37M | $34.98M | $28.65M | $28.09M | $28.14M | $26.50M | $24.51M | $24.40M | $15.90M | 30.8% | +76.2% |
| Subscription revenue | $28.51M | $24.39M | $21.52M | $20.72M | $20.46M | $21.02M | $20.68M | $21.31M | $21.95M | $22.60M | $23.15M | $23.24M | 14.2% | +39.3% |
| Other revenue | $3.88M | $3.69M | $4.16M | $4.64M | $4.56M | $4.38M | $4.83M | $5.39M | $5.41M | $5.38M | $5.23M | $5.39M | 1.9% | -15.0% |
By region
From the segment and revenue-disaggregation notes of GoodRx's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.